or Try an Advanced Search...

    Technical Analysis for CGON - CG Oncology, Inc.

    Grade Last Price % Change Price Change
    F 27.32 5.73% 1.48
    CGON closed up 5.73 percent on Tuesday, May 14, 2024, on 2.21 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong N/A Down Down
    Historical CGON trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish 0.00%
    Slingshot Bearish Bearish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 5.73%
    Lower Bollinger Band Walk Weakness 5.73%
    New 52 Week Low Weakness 5.73%
    Wide Bands Range Expansion 5.73%
    Older End-of-Day Signals for CGON ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 11 hours ago
    Rose Above Previous Day's High about 14 hours ago
    Up 1 ATR about 14 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    2x Volume Pace about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CGON Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus

    Is CGON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 CG Oncology upgraded by Goldman Sachs on recent clinical data
    May 9 CG Oncology, Inc. reports Q1 results
    May 9 CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
    May 6 CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
    May 3 CG Oncology reports data from Phase 3 bladder cancer study
    May 3 CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
    May 3 Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    May 3 Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
    Apr 26 CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
    Apr 24 CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
    See more CGON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 50.23
    52 Week Low 25.77
    Average Volume 654,870
    200-Day Moving Average 0.00
    50-Day Moving Average 37.65
    20-Day Moving Average 35.16
    10-Day Moving Average 32.96
    Average True Range 3.53
    RSI (14) 31.51
    ADX 25.69
    +DI 11.72
    -DI 32.15
    Chandelier Exit (Long, 3 ATRs) 36.41
    Chandelier Exit (Short, 3 ATRs) 36.35
    Upper Bollinger Bands 44.23
    Lower Bollinger Band 26.09
    Percent B (%b) 0.07
    BandWidth 51.59
    MACD Line -2.74
    MACD Signal Line -1.54
    MACD Histogram -1.2019
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 31.21
    Resistance 3 (R3) 31.50 30.50 30.56
    Resistance 2 (R2) 30.50 29.51 30.35 30.34
    Resistance 1 (R1) 28.91 28.90 28.41 28.62 30.13
    Pivot Point 27.91 27.91 27.66 27.76 27.91
    Support 1 (S1) 26.32 26.92 25.82 26.03 24.51
    Support 2 (S2) 25.32 26.31 25.17 24.30
    Support 3 (S3) 23.73 25.32 24.08
    Support 4 (S4) 23.44